natgillin/translations-raw huggingface dataset:
The method according to one of the preceding claims, wherein the composition of the atmosphere in step b) is adjusted on the basis of the percentages of CO and CO2 by weight on the total weight of the atmosphere of the treatment furnace, detected by CO and CO2 analyzers. 
Postupak u skladu s jednim od prethodnih patentnih zahtjeva, naznačen time, da se sastav atmosfere u koraku b) prilagođava na temelju postotaka težinskog udjela CO 1 CO, u odnosu na ukupnu težinu atmosfere peći za obradu, izmjereno CO i CO, analizatorima.
A “therapeutically effective amount” means the amount that, when administered to a mammal, especially a human, for effecting treatment by one of the therapeutic methods, is sufficient to effect treatment for the condition that is the object of that therapeutic treatment. 
Â« Terapeutski učinkovita količina Â« znači količinu koja, kad se daje sisavcima, naročito čovjeku, za učinkovito liječenje jednom od terapeutskih metoda, je dostatna za učinkovit tretman uvjeta koji su predmet terapijskog tretmana.
M FA: Molecular mass of the carboxylic acid 
Datum podnošenja europske prijave patenta:
Example 1 of the 6,911,453 patent): 
Datum podnošenja europske prijave patenta:
Compact fluorescent lamp according to claim 1 or 2, characterized in that it is provided with a driving means (8) by use of which the compact fluorescent lamp can be installed into a lamp socket or can be removed from the same without grasping any of the light-radiating members (4). 
Kompaktna fluorescentna žarulja prema zahtjevu [ili 2, naznačena time što dolazi s pokretnim sredstvima (8) čijom se uporabom kompaktna fluorescentna žarulja može instalirati u utikač za žarulju ili se iz njega može izvaditi bez hvatanja bilo koje cijevi za isijavanje svjetla (4).
or A1 and A2 may be taken together with their attached nitrogen to form a ring selected from the group consisting of: thiomorpholinyl, piperidinyl, pyrrolidinyl, and morpholinyl; wherein said piperidinyl, pyrrolidinyl, and morpholinyl are optionally substituted with CF3, CH2CH2F, C(1-2)alkyl, -CN, OH, CH2OH, or CH2F and up to three additional substituents selected from the group consisting of CH3 and F; 
tiomorfolinil, piperidinil, pirolidinil, i morfolinil; gdje spomenuti piperidinil, pirolidinil, i morfolinil su opcionalno supstituirani sa CF3, CH2CH2F, C(1-2)alkil, -CN, OH, CH2OH, ili CH2F i do tri dodatna supstituenta izabrana iz grupe koja obuhvaća CH3 i F;
A particular example of a group R1-X1- is methoxy. Suitably m is 1,2 or 3. 
Konkretan primjer R'-X- skupine je metoksi. Poželjno je m jednak 1, 2 ili 3.
In a preferred embodiment of the present invention the fatty acid ester group which is covalently bound to the substituted trisaccharide core is an ester of a straight, branched, saturated or unsaturated fatty acid with a chain length of 4 to 20 carbon atoms, preferably 6 to 18, more preferably 8 to 16 carbon atoms, most preferably 10-14 and highly preferred 12 carbon atoms. 
Upotreba u skladu s bilo kojim od patentnih zahtjeva 1-4, naznačena time što je esterska skupina masne kiseline ester nerazgranate, razgranate, zasićene ili nezasićene masne kiseline s duljinom lanca od 4 do 20 atoma ugljika, po mogućnosti 6 do 18, poželjnije 8 do 16 atoma ugljika, najpoželjnije 10 do 14 atoma ugljika, krajnje poželjno 12 atoma ugljika.
In the event of failure of communication between the transmitter and the receiver, the receiver automatically places the engines in a “neutral” setting, and activates an acoustic signal to warn the operator that communication with the transmitter has been lost. 
U slučaju greške u vezi između odašiljača i prijemnika, prijemnik automatski postavlja motore u neutralni položaj, te aktivira zvučni signal kako bi upozorio operatera da je veza između odašiljača i prijemnika prekinuta.
The anti-IL-5 antibody for the use according to claim 1, wherein said composition comprising at least one anti-IL-5 antibody is to be administered subcutaneously. 
Protutijelo protiv IL-5, namijenjeno upotrebi u skladu s patentnim zahtjevom 1 ili patentni zahtjev 2, naznačeno time što navedeni pripravak koji sadrži najmanje jedno protutijelo protiv IL-5 treba primijeniti supkutano.
Note that in each case, the outputs of the receiver are not connected directly to the engines, thrusters, or winch, but rather are connected to the levers, joysticks, or the anchor winch command switch. 
Treba primijetiti da u svim slučajevima izlazi prijemnika nisu spojeni izravno na motore, vijke ili vitlo, nego prije na poluge, palice ili upravljačku sklopku sidrenog vitla.
glycerine in an amount of from 15% to 30%, present in an amount by weight of the total composition, wherein the bulking agent is selected from talc, kaolin, calamine, magnesium carbonate and mixtures thereof, and wherein the surfactant is selected from the group consisting of sodium laureth sulfate, sodium lauryl sulfate, cocamide diethanolamine, lauryl betaine, sodium lauroyl sarcosinate, and mixtures thereof; 
glicerin u količini od 15% do 30%, prisutne u količini po masi ukupnog pripravka, pri čemu je punilo odabrano od talka, kaolina, kalamina, magnezijevog karbonata i njihovih smjesa, te pri čemu je surfaktant odabran iz skupine koju čine natrijev lauret sulfat, natrijev lauril sulfat, kokamid dietanolamin, lauril betain, natrijev lauroil sarkozinat, i njihove smjese;
The subject invention also provides a process for validating a batch of N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide or a salt thereof for distribution. The subject invention also provides a process for preparing a pharmaceutical product comprising N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide or a salt thereof and a pharmaceutically acceptable carrier, wherein the pharmaceutical product has not more than a total of 0.5% w/w relative to N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide of the oxidation decomposition products 2-Chloro-6-(1-ethyl-N-methyl-2-oxoindoline-3-carboxamido)benzoic acid, 1H,3H-spiro[5-chloro-1-methylquinoline-2,4-dione-3,3′-[1]ethylindolin-[2]-one], and 5-Chloro-N-ethyl-3-hydroxy-1-methyl-2,4-dioxo-N-phenyl-1,2,3,4-tetrahydro-quinoline-3-carboxamide. 
HR P20140138 T1 PATENTNI ZAHTJEVI Postupak za validaciju šarže farmaceutskog produkta koji sadrži spoj N-etil-N-fenil-1,2-dihidro-4-hidroksi-5-kloro-1-metil-2-oksokinolin-3-karboksamid ili njegovu sol, te farmaceutski prihvatljiv nosilac za distribuciju, naznačen time, da obuhvaća: a) podvrgavanje uzorka šarže ispitivanju stabilnosti; b) određivanje ukupne količine produkta oksidacijskog raspadanja u uzorku šarže nakon ispitivanja stabilnosti: i c) validaciju šarže za distribuciju, samo ako uzorak šarže nakon ispitivanja stabilnosti ne sadrži više od ukupno 0,5 1te2.% produkata oksidacijskog raspadanja N-etil-N-fenil-1,2-dihidro-4-hidroksi-5-kloro-1-metil-2-oksokinolin-3-karboksamida, u odnosu na N-etil-N-fenil-1,2-dihidro-4-hidroksi-5-kloro-1-metil-2-oksokinolin-3-karboksamid.
The method of claim 3 or 7, wherein the fraction represents at least 0.5% of the human genome. 
Postupak prema zahtjevu 1, naznačen time, da frakcija predstavlja najmanje 0,1% ili najmanje 0,5% humanog genoma.
A process for preparing a compound of Formula (I): or a pharmaceutically acceptable thereof, comprising a step of reacting 3-aminophthalic acid or a salt thereof with a 3-aminoglutarimide compound of Formula (X) or a salt thereof: 
(D, ili njegove farmaceutski prihvatljive soli, solvata, polimorfa ili stereoizomera, naznačen time što se sastoji u koraku reakcije 3-aminoftalne kiseline, ili njezine soli, sa spojem 3-aminoglutarimida Formule (X), ili njegovom solju:
wherein the first piston part and the second piston part move co-axially and the piston-lever element is pivotally connected at one end to a piston stem and movement of the piston stem is substantially limited to moving lengthwise along a piston cylinder axis. 
naznačen time da se prvi dio klipa i drugi dio klipa pomiču ko-aksijalno i element klip-poluga je zakretno spojen na jednom kraju na klipnjaču i pomicanje klipnjače je uglavnom ograničeno na uzdužno pomicanje duž osi cilindra klipnjače.
Pharmaceutical composition for the use of claims 1-14, wherein said method is in conjunction with at least one additional treatment method, said additional treatment method comprising administering at least one pharmaceutical composition comprising an active agent other than an 1L-1B antibody or fragment. 
Farmaceutska smjesa za uporabu prema zahtjevima 1-14, gdje se postupak provodi zajedno s barem još jednim dodatnim postupkom liječenja, taj dodatni postupak liječenja obuhvaća primjenu barem jedne farmaceutske smjese koja sadrži djelatnu tvar koja nije 1L-1f5 protutijelo ili fragment.
The invention also relates to pharmaceutical compositions containing a novel salt of omeprazole as active ingredient; to the novel omeprazole salts for use as active therapheutic substances; to the novel omeprazole salts for use in providing gastrointestinal cytoprotective effects in mammals and man; to the novel omeprazole salts for use in the prevention and treatment of gastrointestinal inflammartory diseases in mammals and man; and to the novel omeprazole salts for use in inhibiting gastric acid secretion in mammals and man. The invention also relates to the use of the novel salts of omeprazole for the manufacture of a medicament for the above given indications. 
Izum se također odnosi na farmaceutske kompozicije koje sadrže novu sol omeprazola kao aktivnu komponentu; na upotrebu novih omeprazol soli za osiguranje gastrointestinalnih cito zaštitnih efekata kod sisavaca 1 ljudi; na upotrebu novih omeprazol soli u sprečavanju i tretiranju gastrointestinalnih upalnih bolesti kod sisavaca i ljudi, na upotrebu novih omeprazol soli za sprečavanje sekrecije želučane kiseline kod sisavaca i ljudi, na postupak sprečavanja sekrecije želučane kiseline kod sisavaca i ljudi davanjem spoja formule I; na postupak za tretiranje gastrointestinalnih upalnih bolesti kod sisavaca i ljudi davanjem spoja formule I; i na postupak za osiguranje gastrointestinalnih cito zaštitnih efekata kod sisavaca i ljudi davanjem spoja formule I.
subjects having a serum triacylglycerol level of at least 150 mg/dL, wherein said triacylglycerol level is determined after fasting for at least 8 hours. 
(iv) subjekti koji imaju razinu triacilglicerola u serumu od barem 150 mg/dI., pri čemu se navedena razina triacilglicerola određuje poslije najmanje 8 sati natašte.
In certain aspects, the needle may include a lumen, a tip for piercing a dermis, and at least two injection ports in communication with the lumen, wherein the ports are linearly disposed along an outer surface of the needle. 
HR P20160498 T1 najmanje dva otvora za ubrizgavanje u komunikaciji s lumenom, pri čemu su otvori linearno postavljeni duž vanjske površine igle i u ravnini su s jednom stranom igle.
Chem.; 59; 21; 1994; 6372-6377) with an amine of formula III by standard methods e.g. via the carboxylic acid chloride or activated esters or by the use of carboxylic acids in combination with a coupling reagent such as e.g. dicyclohexyl carbodiimide. 
Chem.; 59; 21: 1994; 6372-6377) s jednim aminom formule III standardnim metodama npr. putem karboksiličnog kiselog klorida ili aktiviranih estera ili korištenjem karboksilične kiseline u kombinaciji s jednim veznim agensom kao što je to dicikloheksil karbodiimid.
The operation and function of the discharge device 1 and its metered dose valve 2 according to the second embodiment are basically the same as the ones of the first embodiment. 
Djelovanje i funkcija naprave za pražnjenje 1 i njezinog ventila za odmjeravanje doze 2 prema drugoj izvedbi je načelno jednaka kao u prvoj izvedbi.
fermentation of the glucose of the hydrolysate, in presence of a fermentative organism, so as to produce a fermentation must; 
- fermentiranja glukoze u hidrolizatu na takav način da se dobije fermentirajući mošt;
The obtained compression mixture was compressed on an automatic rotary press machine, fitted with round punches to give tablet cores, the weight of 10 cores was 300 mg. 
Dobivena kompresijska smjesa komprimirana je na automatskoj rotacijskoj presi i izrezana bušačem, čime su dobivene jezgre tableta. Težina 10 jezgri bila je 300 mg.
An isolated monoclonal antibody, or antigen binding portion thereof, that specifically binds and neutralizes Clostridium difficile (C. difficile) toxin A, wherein the antibody, or antigen binding portion thereof, comprises: 
Izolirano monoklonalno antitijelo ili njegov dio koji se veže za antigen, koji se specfično veže za i neutralizira Clostridium difficile (C. difficile) toksin A, pri čemu antitijelo, ili njegov dio koji se veže za antigen, je naznačeno time što sadrži:
The process of claim 53, wherein Compound 16 is prepared by a process comprising: A process for preparing Compound 21: comprising cyclizing Compound 22: wherein X is selected from the group consisting of S, O, and NH. 
Postupak u skladu s patentnim zahtjevom 53, naznačen time što Spoj 16 se dobiva postupkom koji se sastoji u: [image] Postupak dobivanja Spoja 21:
a data-processing system 7 capable of controlling the movement system 5 and the cooling system 6, and capable of controlling the receiving, the preservation and the releasing of the bags; and also capable of exchanging data regarding the blood bags from and to the external environment (see FIG. 4). 
- > sustav za obradu podataka 7 koji može upravljati sustavom za pomicanje 5 i sustavom za hlađenje 6, i koji može upravljati preuzimanjem, čuvanjem i izdavanjem vrećica; i koji sustav također može izmjenjivati podatke koji se odnose na vrećice krvi koje dolaze iz vanjskog prostora i koje odlaze u vanjski prostor (vidi sliku 4).
An intermediary position is shown in FIG. 2 b where the container 2 and the base unit 3 have moved a distance downwards. 
Međufazni položaj prikazan je na slici 2b, gdje su se spremnik 2 i osnovna jedinica 3 malo pomaknuli prema dolje.
Step 3: Synthesis of compound (d) 
Korak 3 Sinteza spoja (d)
The composition of claim 1, wherein the isolated peptide is an isolated antibody or antibody fragment. 
Izolirano monoklonsko protutijelo koje se selektivno veže na ABCBS5 prema zahtjevu 1, naznačeno time da se izolirano monoklonsko antitijelo veže na ljudski ABCBS5.
The method according to any one of the preceding embodiments, wherein the method further comprises a step e), wherein step e) comprises removing at least part of one cation from the AX-REED liquid, while retaining at least 65% of said at least one micro-nutrient in said liquid, thereby obtaining a CX-REED liquid, wherein said cation is removed through an Cation Exchange Reverse Electro-Enhanced Dialysis (CX-REED) membrane stack, said membrane stack containing at least one cell consisting of: 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time što postupak nadalje obuhvaća korak e), pri čemu korak e) obuhvaća uklanjanje najmanje dijela jednog kationa 1z tekućine AX-REED uz zadržavanje najmanje 65 % navedene najmanje jedne mikro hranjive tvari u navedenoj tekućini, te se tako dobiva tekućina CX-REED, pri čemu se navedeni kation uklanja putem stoga membrana za kationsku izmjenu reverznom elektro poboljšanom dijalizom,,Cation Exchange Reverse Electro-Enhanced Dialysis" (CX-REED), te navedeni stog membrana sadrži i)
is a hydrogen atom or fluorine atom or chlorine atom; 
- X, je vodikov atom ili fluorov atom ili klorov atom;
To a suspension of 12.85g (321.28 mmol) of sodium hydride (60% suspension in mineral oil) in 500ml of anhydrous tetrahydrofuran at 0°C, was added 56.91g (321.28 mmol) of diethyl-(cyanomethyl)-phosphonate over a 10-min period. 
U suspenziju 12,85 g (321,28 mmol) natrijevog hidrida (60 % suspenzija u mineralnom ulju) u 500 ml bezvodnog tetrahidrofurana, na 0 *C, 10 minuta se dodaje 56,91 g (321,28 mmol) dietil-(cijanometil)-fosfonata.
a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:123 and a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:122; 
(h) -VH sekvencu koja ima najmanje 95% identiteta sekvence od aminokiselinske sekvence SEQ ID NO: 123i VL sekvencu koja ima najmanje 95% identiteta sekvence od aminokiselinske sekvence SEQ ID NO: 122;
The compound of Claim 1, wherein the compound is represented by the following structural formula: or a pharmaceutically acceptable salt thereof. 
5. = Spoj sukladno zahtjevu 1, naznačen time, da je spoj predstavljen slijedećom strukturnom formulom:
Preferably the treatment of infertility comprises a step of determining (e.g. measuring) the serum AMH level of the patient, and administering the dose to a patient having serum AMH level of ≥15 pmol/L. In one embodiment, the product is for use in the treatment of infertility in a patient having serum AMH level of 15 to 24.9 pmol/L, and the product is for administration at a (e.g. daily) dose of, or dose equivalent to, 0.14 to 0.19 µg human derived recombinant FSH (preferably 0.15 to 0.16 µg human derived recombinant FSH) per kg bodyweight of the patient. 
HR P20190023 T1 PATENTNI ZAHTJEVI Proizvod, koji sadrži rekombinantni folikulostimulirajući hormon (FSH) dobiven iz ljudske stanične linije za uporabu kod liječenja neplodnosti kod pacijenta, koji ima razinu AMH u serumu >15 pmol/L, naznačen time da se proizvod administrira u dozi od 0,09 do 0,19 ug rekombinantnog FSH dobivenog iz ljudske stanične linije po kilogramu tjelesne težine pacijenta dnevno; pri čemu liječenje neplodnosti sadrži korak određivanja razine AMH u serumu kod pacijenta i korak administracije doze pacijentu, koji ima definiranu razinu AMH u serumu.
The resulting low calorie ice cream has a softness that can be even higher than ice cream containing sugar. 
Tako dobiveni, niskokalorični sladoled posjeduje mekoću koja je čak i veća od mekoće sladoleda koji sadržava šećer.
The pharmaceutical composition according to claim 13, comprising a pharmaceutically acceptable carrier. 
Farmaceutska kompozicija sukladno zahtjevu 11, koja sadrži farmaceutski prihvatljivi nosač.
Q is hydrogen, alkyl, heterocyclyl or aryl; 
Q je vodik, alkil ili skupina sljedeće formule R2
The compound of claim 2 selected from the group consisting of: 
Spoj prema zahtjevu 2 izabran iz grupe koja obuhvaća:
The process according to any of the foregoing claims, characterised in that it also comprises, at the planned end of the storage step (120), a step (160) of checking the chemical composition of the mixture relative to reference parameters and, if the reference parameters are not adhered to, an extension of the storage step (120) with wetting for an additional or predetermined period of lime or a period defined according to the result of the step (160) of checking the composition. 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time što također obuhvaća, na planiranom kraju koraka čuvanja (120), korak (160) provjere kemijskog sastava smjese u usporedbi s referentnim parametrima 1, ako postoji odstupanje od referentnih parametara, produljenje koraka čuvanja (120) s vlaženjem kroz dodatni ili unaprijed određeni vremenski period ili period definiran prema rezultatima koraka (160) provjere sastava.
In an exemplary embodiment, the hemoglobin of the covalent conjugate is deoxygenated or bound to CO. 
Pripravak sukladno zahtjevu 1, pri čemu je hemoglobin vezan za CO.
or salt thereof; and reacting said compound of Formula VI, or salt thereof, with CH3NH2 to form a compound of Formula V: 
reakciju navedenog spoja s Formulom VI, ili njegove soli, s CH3NH2 da se dobije spoj s formulom V ili njegova sol.
A sheet as claimed in claim 4, wherein the base of each depression comprises a first radius dr 1 in a first direction, a second radius dr 2 in a second direction along the length of the sheet material, the first direction being different from the second direction, wherein the radius of curvature along the first radius dr 1 is different from the radius of curvature along the second radius dr 2 . 
Lim (10) prema zahtjevu 1 ili 2, naznačena time da osnovica svake udubine (12) sadrži prvi radijus u prvom smjeru, drugi radijus u drugom smjeru uzduž duljine limenog materijala (10), te je prvi smjer različit od drugog smjera, pri čemu radijus zakrivljenosti uzduž prvog radijusa je različit od radijusa zakrivljenosti uzduž drugog radijusa.
Recombinant FSH according to claim 1 comprising a2,3-sialylation in an amount which is from 80 to 90% of the total sialylation of the recombinant FSH. 
3. = Postupak prema patentnom zahtjevu 1 ili 2, naznačen time da je 10% do 90% ukupne sialilacije 02,3-sialilacija.
is selected from the group consisting of hydrogen, alkyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heterocycle, heteroarylalkyl, and (NRCRD)sulfonyl; and 
Rg je odabran iz skupine koja se sastoji od vodika, alkila, arilalkila, cikloalkila, cikloalkilalkila, heterocikla, heteroarilalkila i (NRcRp)sulfonila; i
A method of inducing an immune response in an individual comprising the steps of administering to the individual an effective amount of a recombinant staphylococcal clumping factor A (ClfA) or fragment thereof comprising at least amino acid residues 221 to 531 of the fibrinogen binding region (Region A), characterized by at least one amino acid residue substitution or deletion at amino acid residue Ala254, Tyr256, Pro336, Tyr338, Ile387, Lys389, Glu526 and/or Val527 to result in a recombinant fibrinogen binding protein with reduced ability or lacking the ability to non-covalently bind fibrinogen; and stimulating a greater antibody immune response than the wild type ClfA protein. 
1 ili sekvenci s barem 85%, poželjno barem 95% identičnosti sekvence u odnosu na SEQ ID No. 1 ili njegov fragment koji obuhvaća barem aminokiselinske ostatke 221 do 531 regije koja veže fibrinogen (Regija A), naznačeno barem jednom supstitucijom ili delecijom aminokiselinskog ostatka na aminokiselinskom ostatku Ala254, Tyr256, Pro336, Tyr338, Ile387, Lys389, Glu526 i/ili Val527 da se dobije rekombinantni fibrinogen vezujući protein sa smanjenom sposobnosti ili bez sposobnosti nekovalentnog vezanja fibrinogena što će stimulirati veći imuni odgovor od divljeg tipa CIfA proteina, za uporabu u liječenju ili prevenciji stafilokoknih infekcija.
2 is in linear form. 
2 je u linearnom obliku.
A tablet may be made by compression or moulding, optionally with one or more accessory ingredients. 
Tableta se može izrađivati komprimiranjem ili lijevanjem u kalup, po izboru s jednom ili više pomoćnih tvari.
Pharmaceutical composition for treating a metabolic syndrome 
FARMACEUTSKI PRIPRAVAK ZA LIJEČENJE METABOLIČKOG SINDROMA
The compound for use according to any one of claims 1 to 16, wherein the polypeptide is selected from the group consisting of: 
Tvar za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 16, pri čemu je polipeptid odabran iz grupe koja se sastoji od:
In the case where B is —NR2—, —CH2NR2— or —CH2CH2NR2—, for example, the compounds of formula I can be prepared by coupling a compound of the formula II with a compound of the formula III. 
U slučaju gdje B je -NR"-, ili -CH2CH>NR*-, na primjer, spojevi formule I mogu se prirediti sprezanjem spoja formule II sa spojem formule III.
The formulation according to any one of the preceding items, wherein the fumaric acid ester is a mono-(C1-C5) alkylester of fumaric acid that is present in the form of a pharmaceutically acceptable salt. 
Formulacija prema bilo kojem prethodnom zahtjevu, naznačena time, da ester fumarne kiseline je mono-(Ci-Cs) alkilester fumarne kiseline koji je prisutan u obliku farmaceutski prihvatljive soli.
The reaction mixture was diluted with water and extracted with ethyl acetate (3×200 mL). 
Reakcijska smjesa razrijeđena je vodom i ekstrahirana etil-acetatom (3 x 200 mL).
In some embodiments, the neuropathic pain is a central pain syndrome caused by spinal cord injury. In some embodiments, the neuropathic pain is a central pain syndrome caused by a spinal cord contusion. 
Spoj za upotrebu prema bilo kojem od zahtjeva 1 do 3, naznačen time da neuropatska bol je središnji bolni sindrom uzrokovan ozljedom leđne moždine i/ili kontuzija leđne moždine.